Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 2 of 24
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
15.03.2022
Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
In The News
08.03.2022
MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease
Press Release
09.03.2022
Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting
Press Release
18.02.2022
Nalu Medical Inc. Announces $104 Million Equity Financing
Press Release
16.02.2022
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
Press Release
11.01.2022
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
Press Release
15.12.2021
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release
06.12.2021
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Press Release
02.12.2021
AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
Press Release
02.12.2021
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Press Release
©2022 Advent Life Sciences